Efficacy of Melanostop Peeling for Improvement of Melasma
Launched by VIST - FACULTY OF APPLIED SCIENCES · Jan 30, 2019
Trial Information
Current as of June 21, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Adult women aged between 20-50 years old.
- • Melasma on the face
- • Fitzpatrick phototypes I-IV
- • Presenting facial melasma
- • In good health condition
- Exclusion Criteria:
- • Breastfeeding and pregnancy
- • Women presenting oral herpes
- • Other skin diseases, arthritis, diabetes, diseases of thyroid gland
- • Any known allergies to ingredients of the products used in the study
- • Systemic or topical use of corticosteroids in the previous 6 months
- • Antiaging or lightening cosmetic/estetic procedures in the last 2 months (for example: laser or IPL treatments, chemical peels,..)
- • Taking drugs for skin lightening in the previous 2 months
- • Smoking
- • Lesions of unknown origin
- • Oral or topical use of isotretinoin in the previous 6 months
- • Active bacterial, viral or fungal infections of the skin
- • Presence of keloid scars
- • Immunodeficiency
- • Moderate to severe acne
- • Planned change in hormonal contraception or taking drugs that have an affect on hormonal balance during the course of the study
- • Unrealistic expectations
- • Refusal to use sunscreen protection and complying with instructions
About Vist Faculty Of Applied Sciences
VIST - Faculty of Applied Sciences is a leading academic institution dedicated to advancing research and innovation in the field of applied sciences. With a robust focus on interdisciplinary collaboration, VIST engages in cutting-edge clinical trials designed to explore new therapeutic approaches and enhance patient care. The faculty is committed to rigorous scientific methodologies, ethical practices, and the translation of research findings into real-world applications. By fostering partnerships with healthcare providers and industry stakeholders, VIST aims to contribute significantly to the advancement of medical knowledge and improve health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ljubljana, , Slovenia
Patients applied
Trial Officials
Katja Žmitek, PhD
Study Chair
Head of Reasearch Group
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials